Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-17-008470
Filing Date
2017-08-09
Accepted
2017-08-09 17:01:26
Documents
46
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q 2017 Q2 q2201710q.htm 10-Q 676794
2 EXHIBIT 31.1 q22017-exhibit311.htm EX-31.1 16027
3 EXHIBIT 31.2 q22017-exhibit312.htm EX-31.2 16036
4 EXHIBIT 32.1 q22017-exhibit321.htm EX-32.1 8331
  Complete submission text file 0001628280-17-008470.txt   2729549

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT cpix-20170630.xml EX-101.INS 422764
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20170630.xsd EX-101.SCH 21654
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cpix-20170630_cal.xml EX-101.CAL 48615
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cpix-20170630_def.xml EX-101.DEF 79763
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20170630_lab.xml EX-101.LAB 304400
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20170630_pre.xml EX-101.PRE 168067
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: 10-Q | Act: 34 | File No.: 001-33637 | Film No.: 171018717
SIC: 2834 Pharmaceutical Preparations